AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15841817 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis with 5-year caries increment as dependent variable
Number of subjects: 105
Study 15841817 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatments provided during the 5-year interval
Number of subjects: 105
Study 11532385 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 57227A (2.5, 5, 10, 20, 40 mg o.d. and 20 mg b.i.d.)
Number of subjects: 70
Study 11532385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9661091 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 31
Study 9661091 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 31
Study 8089287 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% doxepin cream
Number of subjects: 270
Study 8089287 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 270
Study 3378662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrothricin rinse
Number of subjects: 12
Study 3378662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine rinse
Number of subjects: 12
Study 3378662 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen peroxide rinse
Number of subjects: 12
Study 3378662 — intervention group
Group type: COMPARATOR
Intervention: Ethanol rinse
Number of subjects: 12
Study 3378662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge with 4 mg tyrothricin
Number of subjects: 12
Study 3378662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge with 10 mg tyrothricin
Number of subjects: 12
Study 3378662 — intervention group
Group type: COMPARATOR
Intervention: Parafilm
Number of subjects: 12
Study 31383435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet almond syrup
Number of subjects: 50
Study 31383435 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 50
Study 28474076 — intervention group
Group type: EXPERIMENTAL
Intervention: Special health training and various related health education activities for a period of 1 year
Number of subjects: 330
Study 28474076 — intervention group
Group type: COMPARATOR
Intervention: No special health education and behavior intervention
Number of subjects: 330
Study 26728648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER (30-90 mg every 12 hours)
Number of subjects: 625
Study 26728648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 26728648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Number of subjects: 625
Study 23439744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin with metformin (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin)
Number of subjects: 56
Study 21639998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluents A (50% glycerin and water)
Number of subjects: 30
Study 21639998 — intervention group
Group type: COMPARATOR
Intervention: Diluents B (0.4% phenol and water)
Number of subjects: 30
Study 18338161 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal formulary training (PF)
Number of subjects: 583
Study 18338161 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing formulary training (EF)
Number of subjects: 583
Study 18338161 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 583
Study 17112371 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided cannulation
Number of subjects: 450
Study 17112371 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 450
Study 12600402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural self-esteem intervention as an adjunct to treatment as usual (TAU)
Number of subjects: 0
Study 12600402 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 10699514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administered via Combitube (2.0 mg/kg, diluted with 0.9% saline to a minimum total volume of 10 mL)
Number of subjects: 27
Study 10699514 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube administration of lidocaine (2.0 mg/kg)
Number of subjects: 27
Study 9175114 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeblink conditioning with a 1000 Hz tone as the conditioning stimulus and a corneal airpuff as the unconditioned stimulus
Number of subjects: 2
Study 9175114 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeblink conditioning
Number of subjects: 2
Study 9175114 — intervention group
Group type: COMPARATOR
Intervention: Subjects who failed to show eyeblink conditioning
Number of subjects: 2
Study 9175114 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal activity (measured by the power associated with the respiratory peak in the heart rate spectrum)
Number of subjects: 2
Study 8380131 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy
Number of subjects: 130
Study 8380131 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP chemotherapy plus radiotherapy
Number of subjects: 130
Study 8380131 — intervention group
Group type: COMPARATOR
Intervention: CAP chemotherapy
Number of subjects: 130
Study 6325612 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraneous conversation used as a distractor during skill demonstration of intramuscular injections (experimental group)
Number of subjects: 50
Study 6325612 — intervention group
Group type: COMPARATOR
Intervention: No verbal distraction during skill demonstration (control group)
Number of subjects: 50
Study 31074654 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat therapy (PHT)
Number of subjects: 20
Study 31074654 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 20
Study 30684325 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and pioglitazone
Number of subjects: 95
Study 30684325 — intervention group
Group type: COMPARATOR
Intervention: Metformin and sulphonylureas
Number of subjects: 95
Study 27002445 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 342
Study 27002445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 342
Study 27002445 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 342
Study 25304365 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing combined with community-based health insurance and pro-poor targeting
Number of subjects: 21
Study 20064698 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM) training
Number of subjects: 43
Study 20064698 — intervention group
Group type: COMPARATOR
Intervention: Control training (irrelevant reaction-time test)
Number of subjects: 43
Study 20064698 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment success and relapse up to 3 months after the intervention
Number of subjects: 43
Study 16282296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine 1.75 mg/kg/day
Number of subjects: 95
Study 16282296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine 2.0 mg/kg/day
Number of subjects: 95
Study 16282296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine 2.5 mg/kg/day
Number of subjects: 95
Study 16282296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine 3.0 mg/kg/day
Number of subjects: 95
Study 16282296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all doses)
Number of subjects: 95
Study 9875118 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 12
Study 7526528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation alone and in combination with androgen deprivation therapy
Number of subjects: 76
Study 7526528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapies (radiation, chemotherapy, androgen deprivation)
Number of subjects: 76
Study 7526528 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 76
Study 7526528 — intervention group
Group type: COMPARATOR
Intervention: Prostate cancer-specific survival
Number of subjects: 76
Study 7526528 — intervention group
Group type: COMPARATOR
Intervention: Clinically detectable recurrence (excluding PSA)
Number of subjects: 76
Study 7526528 — intervention group
Group type: COMPARATOR
Intervention: Recurrence (including PSA)
Number of subjects: 76
Study 7526528 — intervention group
Group type: EXPERIMENTAL
Intervention: Local control
Number of subjects: 76
Study 7526528 — intervention group
Group type: COMPARATOR
Intervention: Surgical morbidity
Number of subjects: 76
Study 7526528 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity of adjuvant therapy
Number of subjects: 76
Study 2917584 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 2.5 mg t.d.s.
Number of subjects: 6
Study 2917584 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 2.5 mg t.d.s. (following chronic therapy)
Number of subjects: 6
Study 241600 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g. alclofenac daily
Number of subjects: 76
Study 241600 — intervention group
Group type: COMPARATOR
Intervention: 4.8 g. aspirin daily
Number of subjects: 76
Study 241600 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g. alclofenac tablets
Number of subjects: 76
Study 241600 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g. alclofenac capsules
Number of subjects: 76
Study 29313279 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-767 (400 mg BID)
Number of subjects: 93
Study 27031854 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-Doc
Number of subjects: 1364
Study 27031854 — intervention group
Group type: COMPARATOR
Intervention: FEC120
Number of subjects: 1364
Study 24645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 333
Study 24645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 333
Study 24645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient nutrition
Number of subjects: 333
Study 24645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss in both ears
Number of subjects: 333
Study 24645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 333
Study 24645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 333
Study 24645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 333
Study 24645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 333
Study 22668678 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelsohn maneuver
Number of subjects: 18
Study 20369533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hidden tension suture with absorbable thread (test group)
Number of subjects: 203
Study 20369533 — intervention group
Group type: COMPARATOR
Intervention: Common interrupted suture (control group)
Number of subjects: 203
Study 18778948 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 120
Study 18778948 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 120
Study 16137951 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplement containing isoflavones
Number of subjects: 0
Study 16137951 — intervention group
Group type: COMPARATOR
Intervention: Food enriched with isoflavones
Number of subjects: 0
Study 12897218 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of retinol (209 micro mol) supplementation to mothers
Number of subjects: 150
Study 12897218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 150
Study 10383510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg or 30 mg
Number of subjects: 214
Study 10383510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 8682467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (5 ml applied to the liver cut surface)
Number of subjects: 77
Study 8682467 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 77
Study 2067772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical oxytocin
Number of subjects: 100
Study 2067772 — intervention group
Group type: COMPARATOR
Intervention: Peripheral administration of oxytocin
Number of subjects: 100
Study 6602542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin prophylaxis (20 mg/kg/day in two doses for four days)
Number of subjects: 38
Study 6602542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30297258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5min-TI method for data selection
Number of subjects: 44
Study 30297258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5min-SS-4P method for data selection
Number of subjects: 44
Study 30297258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5min-SS-2P method for data selection
Number of subjects: 44
Study 30297258 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC method for data analysis
Number of subjects: 44
Study 30297258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5min-SS-4P method for data analysis
Number of subjects: 44
Study 29269325 — intervention group
Group type: COMPARATOR
Intervention: 9-valent HPV vaccine
Number of subjects: 5312
Study 29269325 — intervention group
Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 5312
Study 27965491 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin
Number of subjects: 80
Study 27965491 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RGIC)
Number of subjects: 80
Study 24490775 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid overload (FO > 2.5 L) group
Number of subjects: 69
Study 24490775 — intervention group
Group type: COMPARATOR
Intervention: Low fluid overload (FO ≤ 2.5 L) group
Number of subjects: 69
Study 24490775 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in fluid overload over 3 months by strict fluid management plan
Number of subjects: 69
Study 24490775 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of HRV indices with hydration status indices
Number of subjects: 69
Study 23072576 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention within 12 hours for TICH
Number of subjects: 840
Study 23072576 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for TICH
Number of subjects: 840
Study 20593910 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 3 mg/kg/day (adjusted to 2 mg/kg/day after first follow-up)
Number of subjects: 63
Study 20593910 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate 30 mg/kg/day (adjusted to 15 mg/kg/day after first follow-up)
Number of subjects: 63
Study 18055993 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) and cyclosporine (CsA)
Number of subjects: 44
Study 18055993 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation from an HLA‐matched unrelated donor
Number of subjects: 44
Study 16181017 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 2045
Study 16181017 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 2045
Study 16181017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study 11904111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily (high dose)
Number of subjects: 253
Study 11904111 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 200 mg daily (low dose)
Number of subjects: 253
Study 11904111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg daily (maintenance therapy)
Number of subjects: 253
Study 11904111 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole troches 10 mg 4 times daily (maintenance therapy)
Number of subjects: 253
Study 11904111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (maintenance therapy)
Number of subjects: 253
Study 11904111 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (maintenance therapy)
Number of subjects: 253
Study 10588452 — intervention group
Group type: COMPARATOR
Intervention: T-cell responses to GAD
Number of subjects: 0
Study 10588452 — intervention group
Group type: COMPARATOR
Intervention: T-cell responses to CVB4
Number of subjects: 0
Study 10588452 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between T-cell responses to GAD and CVB4 in IDDM patients
Number of subjects: 0
Study 7598917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal alfentanil 0.54 mg
Number of subjects: 10
Study 7598917 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) alfentanil 0.54 mg
Number of subjects: 10
Study 2195085 — intervention group
Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy
Number of subjects: 250
Study 2195085 — intervention group
Group type: EXPERIMENTAL
Intervention: cognitive‐behavioral therapy
Number of subjects: 250
Study 2195085 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine plus clinical management
Number of subjects: 250
Study 2195085 — intervention group
Group type: COMPARATOR
Intervention: pill placebo plus clinical management
Number of subjects: 250
Study 665595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonamides
Number of subjects: 201
Study 665595 — intervention group
Group type: COMPARATOR
Intervention: Decongestants
Number of subjects: 201
Study 31267366 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 μg, two inhalations per dose, twice-daily
Number of subjects: 1119
Study 31267366 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol dry powder inhaler (UV DPI) 62.5/25 μg, one inhalation, once-daily
Number of subjects: 1119
Study 28991907 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Start intervention (15 months duration)
Number of subjects: 307
Study 28991907 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 307
Study 25387363 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA 290 (4 mg)
Number of subjects: 0
Study 25387363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24192466 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 30
Study 24192466 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 30
Study 20706141 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP group
Number of subjects: 220
Study 20706141 — intervention group
Group type: COMPARATOR
Intervention: OAA/S group
Number of subjects: 220
Study 21206354 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based instructional manual and Thera-Band resistive bands for upper-body resistance exercise
Number of subjects: 40
Study 21206354 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise recommendations (wait-list control)
Number of subjects: 40
Study 17699311 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/d (EPL50)
Number of subjects: 0
Study 17699311 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg/d (EPL100)
Number of subjects: 0
Study 17699311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17699311 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 17699311 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/d (EPL50) and Eplerenone 100 mg/d (EPL100)
Number of subjects: 0
Study 15515746 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐131 uptake (IU)
Number of subjects: 62
Study 15515746 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐131 whole body scintigraphy (WBS)
Number of subjects: 62
Study 15515746 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium scintigraphy (TS)
Number of subjects: 62
Study 11165408 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine (1200 mg/m² on days 1 and 8, every 3 weeks)
Number of subjects: 49
Study 11165408 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + vinorelbine (gemcitabine at 1000 mg/m² and vinorelbine at 25 mg/m² on days 1 and 8, every 3 weeks)
Number of subjects: 49
Study 9644706 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal smoking‐cessation intervention (n = 14)
Number of subjects: 28
Study 9644706 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 14)
Number of subjects: 28
Study 7639368 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (5 mg in 10 mL of 0.9% saline)
Number of subjects: 20
Study 3297940 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (Wellferon)
Number of subjects: 30
Study 3297940 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 30
Study 31298927 — intervention group
Group type: COMPARATOR
Intervention: Dorsiflexion closing wedge metatarsal osteotomy (DCWMO)
Number of subjects: 27
Study 31298927 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteochondral autologous transplantation (OAT)
Number of subjects: 27
Study 30820008 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 76
Study 30820008 — intervention group
Group type: COMPARATOR
Intervention: Aromatase Inhibitors (AI)
Number of subjects: 76
Study 30820008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Growth Hormone and Aromatase Inhibitors (AI/GH)
Number of subjects: 76
Study 26479711 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic beverage (L. casei, 10^11 colony-forming units·day‐1)
Number of subjects: 8
Study 26479711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 24447510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the gluteus medius tendon (GMT)
Number of subjects: 16
Study 24447510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the gluteus medius muscle (GMM)
Number of subjects: 16
Study 24447510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the adductor longus tendon (ALT)
Number of subjects: 16
Study 24447510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections into GMT and GMM
Number of subjects: 16